Hepatectomy for Early-stage HCC Patients With CSPH

Clinically significant portal hypertension (CSPH) can affect the surgical prognosis of early-stage (BCLC stage A) HCC. An additional stage, such as the BCLC stage A-B, can be considered.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HCC Digestive System Diseases Hypertension, Portal Liver Diseases Portal Hypertension

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

HCC was diagnosed by two experienced pathologists in Child-Pugh grade A/B negative resection margin Initial diagnosis of HCC in the patients

Exclusion criteria

Distant transfer Not HCC

Treatment and study plan

Hepatectomy

Procedure

Liver resection

Primary outcomes

death

Time frame: 2009--2025

Patient survival time after surgery
recurrence

Time frame: 2009--2025

Patient recurrence time after surgery

Sponsors and collaborators

Lead sponsor

Tongji Hospital

Other

Registry information

Official study title

Clinically Significant Portal Hypertension (CSPH) on Early-stage HCC Following Hepatectomy: What's the Impact?

Important dates

Study start: 2009
Primary completion: 2017
Study completion: 2022
First posted: Jun 2, 2022
Registry last updated: Jun 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting